CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-07 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −949 | $77.91 | $74K | 117,697 |
| 2026-01-07 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −38 | $78.60 | $3K | 117,659 |
| 2026-01-07 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +751 | $38.10 | $29K | 118,410 |
| 2026-01-07 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −471 | $77.10 | $36K | 117,939 |
| 2026-01-07 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −269 | $77.92 | $21K | 117,670 |
| 2026-01-07 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −11 | $78.98 | $869 | 117,659 |
| 2026-01-07 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,625 | 751 | ||
| 2026-01-07 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −751 | 0 | ||
| 2026-01-07 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −1,026 | $77.48 | $79K | 116,077 |
| 2026-01-07 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −52 | $77.48 | $4K | 6,850 |
| 2026-01-07 | Pauwels Eric CHIEF BUSINESS OFFICER | Sale 10b5-1 | −1,352 | $77.48 | $105K | 87,489 |
| 2026-01-06 | Gravier Pierre CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2,139 | $76.95 | $165K | 90,310 |
| 2026-01-06 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −5,149 | $76.95 | $396K | 399,983 |
| 2026-01-06 | Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −1,381 | $76.95 | $106K | 74,962 |
| 2026-01-06 | Golden Lee Scott EVP & CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,340 | $76.95 | $103K | 93,936 |
| 2026-01-06 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,739 | $76.95 | $134K | 119,162 |
| 2026-01-06 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −1,279 | $76.95 | $98K | 117,103 |
| 2026-01-06 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −54 | $76.95 | $4K | 6,902 |
| 2026-01-06 | Pauwels Eric CHIEF BUSINESS OFFICER | Sale 10b5-1 | −1,789 | $76.95 | $138K | 88,841 |
| 2026-01-05 | Reeve Emma Director | Option exercise 10b5-1 | +734 | $46.54 | $34K | 11,400 |
Page 11 of 25 · 493 trades